Mumbai: Metropolis Healthcare Limited reported a 16.6 per cent rise in year on year (YoY) revenue to Rs 450 crore in the first quarter ended June this year.
Ebitda for the quarter stood at Rs 113.2 crore, representing 27.1 per cent growth YoY, while profit after tax was up 25 per cent to Rs 56.9 crore.
The company said its patient volume grew 10 per cent YoY and test volume increased 11 per cent YoY.
While revenue from the business-to-consumer (B2C) segment was up 18 per cent, and business-to-business (B2B) revenue rose 15 per cent YoY in the period.
The company also reported a 6 per cent increase in revenue per patient (RPP) and a 5 per cent rise in revenue per test (RPT), supported by a richer test mix and higher contribution from specialised diagnostics.
Tier 3 cities were the fastest-growing market as revenue increased 25 per cent YoY, compared with 11 per cent growth in Tier 1 and 14 per cent in Tier 2, highlighting the significant growth opportunity beyond large metros, Metropolis added.
Its TruHealth segment saw an increase of 22 per cent in YoY revenue to Rs 81 crore, representing 18 per cent of the total revenue.
While specialty diagnostics grew 17 per cent YoY to Rs 178 crore, contributing to 40 per cent of total revenue for the quarter.
Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited said, “The diagnostics industry is consolidating around trusted, science-led providers as patients increasingly prioritise quality, accuracy and specialised care. Our investments in scientific innovation, strategic acquisitions and network expansion continue to strengthen Metropolis’ leadership across key markets, particularly in North India, while broadening our differentiated diagnostics offering.”
